This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Janine Schuurman, Ph.D.
Biotech Consultant at Lust for Life Science


Janine’s career centers around the antibody molecule: as a biological source of inspiration and as a therapeutic modality.

She holds a PhD in molecular immunology for the University of Amsterdam (1997). After a few post doc positions she joined Genmab in the year 2000 to develop antibody therapeutics, as one of the first ten employees on the R&D team. Throughout her Genmab years she significantly helped propel the discovery and development of investigational therapies to help people with cancer and other diseases.

She is a co-inventor of many therapeutic antibodies including FDA-approved amivantamab (RYBREVANT® Janssen), epcoritamab (EPKINLY® Genmab/Abbvie) and others in clinical and pre-clinical stage. In addition to the above she is a co-inventor of the successful clinically translated bispecific antibody platform DuoBody® and effector function-enhanced HexaBody® platform and the pre-clinical stage HexElect® technology.

She championed many successful academic and industry partnerships in the field of antibody therapeutics and complementary fields of research.

Now an independent biotech consultant (Lust for Life Science B.V.) and thought leader, she is as passionate and active as ever: she collaborates with many organizations and speaks at scientific conferences around the world. She is increasingly focussed on the impact of leadership and organizational culture on innovation, and it is her strong belief that being curious and valuing different expertise and capabilities is key to driving innovative research and new technologies.

Agenda Sessions

  • Co-Chairs' Welcome and Opening Remarks

  • Jim Huston Science Talent Award Winner Presentation: IgE Class Antibody Therapeutics for Cancer

  • Chairman’s Remarks